Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice

European Journal of Haematology

Volumn 98, Issue 5, 2017, Pages 501-507

  Sekine, Masaaki ^a   Kubuki, Yoko ^a   Kameda, Takuro ^a   Takeuchi, Masanori ^b   Toyama, Takanori ^c   Kawano, Noriaki ^d   Maeda, Kouichi ^e   Sato, Seiichi ^f   Ishizaki, Junzo ^g   Kawano, Hiroshi ^b   Kamiunten, Ayako ^a   Akizuki, Keiichi ^a   Tahira, Yuki ^a   Shimoda, Haruko ^a   Shide, Kotaro ^a   Hidaka, Tomonori ^a   Kitanaka, Akira ^h   Yamashita, Kiyoshi ^d   Matsuoka, Hitoshi ^b   Shimoda, Kazuya ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Koga General Hospital   (Japan)

^c Nobeoka Prefectural Hospital   (Japan)

^d MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^e Kokuritsu Miyakonojo Hospital   (Japan)

^f Fujimoto Hospital   (Japan)

^g Aisenkai Nichinan Hospital   (Japan)

^h KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

adult T cell leukemia lymphoma; antibody therapy; CC chemokine receptor 4; mogamulizumab; retrospective

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOXANTRONE; MOGAMULIZUMAB; PIRARUBICIN; PREDNISONE; URAMUSTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FEVER; HUMAN; HYPOXEMIA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; T CELL LEUKEMIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85018759888     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12863     Document Type: Article

References (19)

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481–492.
2. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
3. Adult T-cell leukaemia/lymphoma. In: Swerdlow SH, et al., (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008: 281–284.
4. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428–437.
5. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–5464.
6. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15–20.
7. Ito A, Ishida T, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother. 2009;58:1195–1206.
8. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99:1505–1511.
9. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591–1598.
10. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–842.
11. Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672–682.
12. Matsunaga T, Yamashita K, Kubuki Y, et al. Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan. Int J Hematol. 2012;96:342–349.
13. Kawano N, Kuriyama T, Sonoda KH, et al. Clinical impact of a humanized CCR4 antibody (Mogamulizumab) in 14 patients with aggressive adult T-cell leukemia-lymphoma treated at a single institution during a three-year period (2012-2014). Intern Med. 2016;55:1439–1445.
14. Iyama S, Sato T, Ohnishi H, et al. A multicenter retrospective study of mogamulizumab efficacy in adult T-Cell leukemia/lymphoma. Clin Lymphoma Myeloma Leuk. 2016;17:31–37.
15. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453–459.
16. Institute NC. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). NIH. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed May 29, 2009.
17. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 1999;400:776–780.
18. Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–1640.
19. Fukushima T, Nomura S, Shimoyama M, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166:739–748.